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Musculoskeletal diseases represent a major challenge to patient, clinical and scientific com-
munities. Chronic joint pain, inflammation, stiffness and joint damage characteristic features
of this group of diseases. The term arthritis refers to inflammation within a joint. In addition
to impacting day-to day activities, arthritis can result in disability through irreversible joint
damage and co-morbidities such as cardiovascular disease, hypertension and depression.
For the clinician, suppression of inflammation is paramount to prevent some of the long
term associated morbidity and mortality. Current ‘treat-to-target’ regimens are aimed at estab-
lishing disease remission as early as possible after diagnosis. However, beyond conventional
measures of inflammation, a key feature of many musculoskeletal conditions, few specific
biological markers exist to assist in the management of these complex conditions. C-reactive
protein is frequently used either in isolation or in combination with disease activity scoring
systems to assess treatment efficacy. Its use however belies the multifactorial nature of many
of these conditions. Put simply, the current tests do not accurately reflect the complexity of the
disorders we are attempting to treat.
The synovial membrane is the primary site of pathology in inflammatory arthritis. In
arthritis this normally nourishing tissue becomes hyperplastic; activated cells producing a
wide variety of cytokines and proteolytic enzymes as well as chemokines that attract immune
cells and thus perpetuate the inflammatory process. Thus analysis of joint fluid and tissue as
well as blood are ideal sources for novel protein identification in arthritis.
This focus issue on ‘Musculoskeletal diseases’ highlights research and reviews which cut
across a range of diagnoses. There are five research articles and two reviews included: First,
Collins et al. describe a translational research study using synovial membrane biopsies to
identify putative biomarkers of anti—TNF treatment response in psoriatic arthritis patients.
Biologic therapies are often designed to target inflammatory cytokines, and can be extremely
effective in up to 70% of psoriatic arthritis patients. For those who do not respond however
the disease remains active and risk of long-term damage remains. Furthermore the ability
to allocate expensive drugs to the most responsive patients could bring benefit to healthcare
providers also. The authors move from gel based candidate marker discovery to development
of targeted MRM assays. Dwivedi et al. capably illustrate the process and some of the pitfalls
involved in developing targeted mass spectrometry based assays, in the context of rheumatoid
arthritis. Results demonstrate changes in signal to noise ratio dependent on removal of high
abundance proteins such as albumin and immunoglobulin.
The effects of smoking and specifically nicotine on articular chondrocytes, the cells within
joint cartilage, is investigated in the context of osteoarthritis by Lourido et al. The study
combines a metabolic labelling strategy with LC-MALDI-TOF analysis, showing increased
secretion of severalmolecules includingdegradative enzymes.Qundos et al. have used antibody
bead arrays to profile 92 proteins within plasma samples from osteoporosis patients. Autocrine
motility factor receptor (AMFR) emerges as a candidate marker; reduced in osteoporosis. The
authors postulate that the drop in AMFRmay be due to reduced physical activity in the patients.
A broad range of proteomic discovery methods are used by McArdle et al. to differentiate
psoriatic and rheumatoid arthritis. Label-free LC-MS, antibody bead arrays and aptamer array
platforms identified a combined 172 lead proteins that distinguish psoriatic arthritis patients
from those with rheumatoid arthritis. The first of the reviews by Eakin et al. focuses on the
importance of Siglec receptors and ligands regulating tolerance and immune cell activity in
the context of autoimmune disorders, in particular rheumatoid arthritis. Is hypothesized that
glyco-immunological pathways could be used as surrogate measures or disease activity or
targets for novel treatments. Finally, Hinchliffe et al. overviews the current knowledge on the
C© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
624 Proteomics Clin. Appl. 2016, 10, 623–624
use of array platforms to detect novel autoantigens and autoantibodies for better management
of Lupus.
In recent years proteomics research has offered the opportunity to study musculoskeletal
disorders in a more holistic fashion. Many studies have collectively given fresh insight into
disease mechanisms, identified potential biomarkers to manage treatment, monitor disease
activity and generated new hypotheses to test. Translating these findings into the clinic to
improve the lives of patients remains a major hurdle. As proteomic technologies improve
in terms of sensitivity, precision and robustness we can start to envision a future where
multiplex platforms, whether array or mass spectrometry based, will be absorbed into clinical
laboratories. There are promising initiatives from proteomics organisations such as HUPO,
EUPA, CPTAC and MSACL which indicate interest in coordinating and accelerating research
efforts. We hope you find the articles in this special issue of interest and wish to thank all the
authors for their valuable contributions.
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